Beacon Pharmaceuticals PLC (DSE:BEACONPHAR)

Market Cap	26.40B +2.1%
Revenue (ttm)	15.57B +30.2%
Net Income	1.46B +74.1%
EPS	6.31 +74.1%
Shares Out	231.00M
PE Ratio	18.12
Forward PE	n/a
Dividend	2.10 (1.83%)
Ex-Dividend Date	Nov 17, 2025

Volume	616,634
Open	n/a
Previous Close	114.90
Day's Range	113.70 - 117.90
52-Week Range	96.00 - 147.50
Beta	-0.38
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 29, 2026

About Beacon Pharmaceuticals

Beacon Pharmaceuticals PLC engages in the producing and promoting of pharmaceuticals finished formulations, lifesaving intravenous fluids, active pharmaceutical ingredients, bio-tech, and genetic engineering products in Bangladesh and internationally. The company offers general, oncology, biotech, and chronic care products. It also provides products in various therapeutic categories such as oncology, hematology, anti-cancer, hepatology, nephrology, antibiotics, analgesics, anti-diabetics, respiratory, cardiovascular, dermatology, gastrointestin...

• Industry: Pharmaceutical Preparations
• Founded: 2001
• Employees: 4,771
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: BEACONPHAR

Financial Performance

In fiscal year 2025, Beacon Pharmaceuticals's revenue was 12.54 billion, an increase of 17.20% compared to the previous year's 10.70 billion. Earnings were 946.51 million, an increase of 81.67%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jul 6, 2026

Data Sources Report a data error